History of CyberKnife

In 1987, John R. Adler, MD, professor of neurosurgery and radiation oncology at Stanford University Medical Center, developed the CyberKnife System after completing a fellowship in Sweden with Lars Leksell, MD, who is the founder of radiosurgery. With the CyberKnife System, Adler’s vision was to develop a non-invasive robotic radiosurgery system with superior accuracy for treatment of tumors anywhere in the body. The revolutionary concept reached far beyond the practice of radiosurgery at the time, which restricted radiosurgery to the treatment of intracranial tumors.

The CyberKnife System is the world’s first and only radiosurgery system designed to treat tumors anywhere in the body with sub-millimeter accuracy. Using image guidance technology and computer controlled robotics, the CyberKnife System is designed to continually track, detect, and correct for tumor and patient movement throughout the treatment. Because of its extreme precision, the CyberKnife System does not require invasive head or body frames to stabilize patient movement, vastly increasing the system’s flexibility.

For more than 30 years, traditional radiosurgery systems, or systems that deliver precise, high dose radiation directly to a tumor, have been used primarily to destroy brain tumors. The CyberKnife System represents the next generation of radiosurgery systems, combining continual image-guidance technology with a compact linear accelerator that has the ability to move in three dimensions, according to the treatment plan. This combination, called intelligent robotics, extends the benefits of radiosurgery to the treatment of tumors anywhere in the body.

The CyberKnife procedure requires no anesthesia, can be performed on an outpatient basis, and allows for the treatment of patients who otherwise would not have been treated with radiation or who may not have been good candidates for surgery. In addition, the CyberKnife procedure avoids many of the potential risks and complications that are associated with other treatment options and is more cost effective than traditional surgery.

The World Health Organization (WHO) estimates that there are 24.6 million people living with cancer worldwide, with approximately 10.9 million new cases being diagnosed every year. To date, Accuray has brought the superior tumor treatment capabilities of the CyberKnife System to more than 200,000 patients around the world, including those with tumors previously considered inoperable or surgically complex.

Since the launch of the CyberKnife System, Accuray has undertaken an aggressive strategy to develop system enhancements that facilitate clinicians’ ability to treat tumors anywhere in the body with the highest levels of accuracy. Currently, Accuray has installed more than 150 CyberKnife Systems worldwide, and a large body of peer-reviewed papers supports its clinical practice. Accuray is committed not only to continuing its tradition of advancing the field of robotic radiosurgery, but also to providing its customers with the highest level of support in its  ongoing efforts to fight cancer.

Accurate Cancer Treatment

CyberKnife can treat benign tumors and many types of cancer, including, brain, head and neck, liver, lung, pancreatic, and prostate cancer, metastases, and spinal tumors.

Robotic Cancer Surgery

The CyberKnife System uses image-guided robotics to precisely destroy cancer tumors and other lesions. This precision spares normal, healthy tissue, while the higher dosage offers improved chances for cure from cancer. The CyberKnife can treat inoperable and hard to reach cancerous tumors.

We Accept Most Insurance Carriers

 

 

We work to obtain pre-authorization with all insurance companies.